Clinical and pathogenetic significance of monocyte chemotactic protein-1 in rheumatoid arthritis: A literature review
Open Access
- 14 September 2026
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 173-181
Abstract
Monocyte chemotactic protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), plays a key role in regulating inflammation in various pathologies. It is directly or indirectly implicated in the pathogenesis of oncologic and pulmonary diseases, neuroinflammatory, cardiovascular, and skin diseases. Its role as a biomarker of disease severity has been proven. The role of this chemokine in the pathogenesis of immune-mediated inflammatory rheumatic diseases remains insufficiently studied and is of considerable scientific interest. The aim of this literature review was to analyze scientific data on the pathogenetic role of MCP-1 in rheumatoid arthritis (RA) and the prospects for its use in clinical practice. A search for scientific publications was performed in the electronic databases PubMed, Google Scholar, and eLIBRARY.RU, published in Russian and English before February 2026. This review of the scientific literature clarified the role of MCP-1 in the pathogenesis of RA and highlighted one of the most pressing areas of scientific research: the development of new drugs (antagonists of the receptor of this chemokine, CCR2). MCP-1 has been shown to play a key role in enhancing the inflammatory cascade and is closely associated with chronic, uncontrolled inflammation. MCP-1 exerts its biological effects on migration, infiltration, and differentiation of immune cells by binding to its receptor, CCR2. The MCP-1 (CCL2)/CCR2 axis is a central inflammatory mechanism that attracts monocytes to the site of inflammation. Currently, proposed CCR2 antagonist drugs are not sufficiently effective, and extrapolation of experimental results in animal models does not justify clinical trials. Nevertheless, the development of new CCR2 antagonists and/or their combination with other immunomodulators may be a promising strategy for improving the effectiveness of RA treatment.Keywords
This publication has 43 references indexed in Scilit:
- The endocannabinoid-derived prostaglandin glycerol esters and prostaglandin ethanolamides modulate intestinal epithelial hallmarks of colitisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2026
- Skin‐Soothing Properties of Juniperus formosana Hayata Revealed by Bioactivity‐Based Molecular NetworkingChemistry & Biodiversity, 2025
- World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2025)Aging Clinical and Experimental Research, 2025
- Identification of critical genes and metabolic pathways in rheumatoid arthritis and osteoporosis toward drug repurposingComputers in Biology and Medicine, 2024
- World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2023)Aging Clinical and Experimental Research, 2023
- Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3/4 and FOXP3) activation.Autoimmunity Reviews, 2022
- MCP-1: Function, regulation, and involvement in diseaseInternational Immunopharmacology, 2021
- The molecular structure and role of CCL2 (MCP‐1) and C‐C chemokine receptor CCR2 in skeletal biology and diseasesJournal of Cellular Physiology, 2021
- Monocyte Chemoattractant Protein-1 (MCP-1) in Inflammatory Joint Diseases and Its Involvement in the Cytokine Network of Rheumatoid SynoviumClinical Immunology and Immunopathology, 1993
- Human monocyte chemoattractant protein‐1 (MCP‐1) Full‐length cDNA cloning, expression in mitogen‐stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JEFEBS Letters, 1989